Preoperative chemotherapy with epidoxorubicin, docetaxel and capecitabine plus pegfilgrastim in patients with primary breast cancer.
The objective of this pilot trial was to evaluate the safety and activity profile of epidoxorubicin, docetaxel and oral capecitabine plus pegfilgrastim (TEX+P) as preoperative first-line treatment for patients with breast cancer. Eleven consecutive patients were enrolled in this prospective clinical pilot trial. Preoperative treatment consisted of epidoxorubicin [75 mg/m2 body surface area (BSA)] and docetaxel (75 mg/m2 BSA) administered sequentially on day 1 in combination with oral capecitabine 2000 mg/m2 daily divided into two doses on days 1-14 of each 3-week treatment cycle. Pegfilgrastim 6 mg fixed dose was administered s.c. on day 2 of every treatment cycle. Patients received a total of 58 cycles (median 6 cycles, range 1-6) of this therapeutic regimen. Outpatient TEX+P was well tolerated. No WHO grade IV toxicity was observed. A pathological major response to this preoperative therapy regimen could be demonstrated in eight of nine evaluable patients leading to breast-conserving surgery in seven of nine evaluable patients. We conclude that outpatient TEX+P is safe in the neoadjuvant treatment of patients with primary breast cancer. Thus, this regimen can be considered for further clinical trials.
Wenzel
Catharina
C
Department of Internal Medicine I, Division of Oncology, University of Vienna, Vienna, Austria.
Bartsch
Rupert
R
Locker
Gottfried J
GJ
Hussian
Dagmar
D
Pluschnig
Ursula
U
Sevelda
Ursula
U
Gnant
Michael F
MF
Jakesz
Raimund
R
Zielinski
Christoph C
CC
Steger
Guenther G
GG
D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D000069287:Capecitabine; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D000077143:Docetaxel; D015251:Epirubicin / Q000008:administration & dosage / Q000031:analogs & derivatives*; D005260:Female; D000069585:Filgrastim; D005472:Fluorouracil / Q000031:analogs & derivatives; D005965:Glucuronates / Q000008:administration & dosage; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage; D006801:Humans; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D009361:Neoplasm Invasiveness / Q000473:pathology*; D010865:Pilot Projects; D011092:Polyethylene Glycols; D011300:Preoperative Care; D011446:Prospective Studies; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism; D011994:Recombinant Proteins; D043823:Taxoids / Q000008:administration & dosage; D016896:Treatment Outcome
D000069287:Capecitabine; D003841:Deoxycytidine; D000077143:Docetaxel; D015251:Epirubicin; D000069585:Filgrastim; D005472:Fluorouracil; D005965:Glucuronates; D016179:Granulocyte Colony-Stimulating Factor; D011092:Polyethylene Glycols; D018719:Erb-b2 Receptor Tyrosine Kinases; D011994:Recombinant Proteins; D043823:Taxoids; C074868:epidoxorubicin glucuronide; C455861:pegfilgrastim